<DOC>
	<DOCNO>NCT02320032</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetics ( PK ) various dos dose interval aripiprazole lauroxil .</brief_summary>
	<brief_title>An Open-Label Study Aripiprazole Lauroxil Subjects With Stable Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Aripiprazole lauroxil</mesh_term>
	<criteria>Has stable schizophrenia schizoaffective disorder Has demonstrate ability tolerate aripiprazole Has stable antipsychotic medication regimen without change least 2 month prior screen Has body mass index ( BMI ) 18.0 35.0 kg/m2 , inclusive Additional criterion may apply Is pregnant , breastfeeding , plan become pregnant study period Has receive aripiprazole lauroxil IM depot aripiprazole within 6 month , longacting , injectable antipsychotic medication within 3 month Is danger himself/herself screen upon admission Has history positive test result human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C Has positive urine drug screen screen Day 1 Additional criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Alkermes</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Aripiprazole lauroxil</keyword>
	<keyword>ALKS 9072</keyword>
</DOC>